Barclays says investors should consider depositing their money in Scotts Miracle-Gro, a pandemic-era beneficiary positioned to generate solid free cash flows ahead. “We expect SMG to deliver an FCF of $6 to $8/share over the next three years from strong US Consumer Fundamentals business and adjusted working capital,” wrote analyst Gaurav Jain. during the upgrade of its stock to an excess rating. “This will help it remove leverage from its current high leverage and help steer the price up.” Among reasons for liking Barclays stock, Jain cited confidence that US consumer margins will stabilize in 2023 and noted that the horticulture business has, in recent history, been weak. perform well in times of economic uncertainty. Monetizing the company’s cannabis business – which Barclays stipulates at zero value – could also benefit the stock further, he said. Barclays’ $75 price target unchanged implies that the stock will be up 45% from Monday’s closing price. Shares were down about 68% this year and up 6% before the bell on Tuesday. – Michael Bloom of CNBC contributed reporting